GAPO syndrome: Difference between revisions
mNo edit summary |
|||
Line 11: | Line 11: | ||
== Overview == | == Overview == | ||
'''GAPO syndrome''' is a rare, autosomal recessive disorder that causes severe growth retardation, and has been observed fewer than 30 times before 2011. GAPO is an acronym that encompasses the predominant traits of the disorder: growth retardation, alopecia, pseudoanodontia (teeth failing to emerge from the gums), and worsening optic atrophy in some subjects. Other common symptoms include premature aging, large, prominent foreheads, and delayed bone aging. GAPO syndrome typically results in premature death around age 30–40, due to interstitial fibrosis and atherosclerosis. | |||
== Historical Perspective == | == Historical Perspective == | ||
GAPO syndrome was first described in 1947. Since then, fewer than 60 cases have been reported in the medical literature up to the year 2021. | |||
== Classification == | == Classification == | ||
GAPO syndrome is caused by homozygous nonsense or splicing mutations in the ANTXR1 gene located on chromosome 2p13.3. This gene encodes anthrax toxin receptor 1, also known as tumor endothelial marker 8 (TEM8). The inheritance pattern is autosomal recessive, and genetic counseling is recommended for at-risk couples to inform them that each pregnancy carries a 25% risk of having an affected child | |||
== Pathophysiology == | == Pathophysiology == | ||
GAPO syndrome is a genetic disorder resulting from mutations in the ANTXR1 gene, leading to dysfunctional anthrax toxin receptor 1. Symptoms may begin to appear in infancy or early childhood. | |||
== | == Cause == | ||
GAPO syndrome is a genetic disease, which means that it is caused by one or more genes not working correctly.Disease-causing variants, or differences, in the following gene(s) are known to cause this disease: ANTXR1 | |||
== | == Clinical features == | ||
* '''Growth Retardation:''' Individuals with GAPO syndrome exhibit slow skeletal formation, resulting in below-average height. | |||
* '''Alopecia (Hair Loss):''' Hair is typically thinly dispersed and fragile, often leading to baldness later in life. | |||
* '''Pseudoanodontia:''' Tooth growth is stunted, with teeth failing to emerge from the gums or develop normally. | |||
* '''Progressive Optic Atrophy:''' Approximately one-third of individuals experience optic nerve atrophy, leading to peripheral vision impairment and difficulty distinguishing colors. | |||
* '''Facial Features:''' While not defining, most individuals with GAPO syndrome have coarse facial features, including a large forehead, depressed nose bridges, protruding ears, and thick lips. | |||
* '''Mental Function:''' There is no direct correlation between GAPO syndrome and mental retardation, although some cases of co-occurrence have been reported. | |||
== Epidemiology and Demographics == | == Epidemiology and Demographics == | ||
Approximately 60 patients with GAPO syndrome have been reported in literature since the first description in 1947. | |||
== Risk Factors == | == Risk Factors == | ||
There are no specific risk factors associated with the development of GAPO syndrome. | |||
== Screening == | == Screening == | ||
There are no established screening programs for GAPO syndrome. | |||
== Natural History, Complications and Prognosis == | == Natural History, Complications and Prognosis == | ||
GAPO syndrome has no curative treatment. Management primarily involves ophthalmologic surveillance and addressing symptomatic health problems. Individuals with GAPO syndrome generally have a reduced lifespan, typically living until the fourth to sixth decade of life. | |||
== Diagnosis == | == Diagnosis == | ||
Diagnosis mostly relies on physical and ophtamologic examination. Additionally skin biopsy, cerebral angiography and magnetic resonance imaging contribute to more specific diagnosis.Prenatal diagnosis is not possible from fetal ultrasound (US). In utero growth retardation may be observed on US but is not specific. | |||
== Treatment == | == Treatment == | ||
There is no curative treatment. Management mostly relies on ophthalmologic surveillance and symptomatic treatment of the multiple health problems.GAPO patients are reported to have a reduced lifespan (until the fourth to sixth decade of life | |||
== References == | == References == |
Revision as of 09:43, 27 September 2023
WikiDoc Resources for GAPO syndrome |
Articles |
---|
Most recent articles on GAPO syndrome Most cited articles on GAPO syndrome |
Media |
Powerpoint slides on GAPO syndrome |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on GAPO syndrome at Clinical Trials.gov Trial results on GAPO syndrome Clinical Trials on GAPO syndrome at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on GAPO syndrome NICE Guidance on GAPO syndrome
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on GAPO syndrome Discussion groups on GAPO syndrome Patient Handouts on GAPO syndrome Directions to Hospitals Treating GAPO syndrome Risk calculators and risk factors for GAPO syndrome
|
Healthcare Provider Resources |
Causes & Risk Factors for GAPO syndrome |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
GAPO syndrome is a rare genetic disorder. GAPO is an acronym for growth retardation, alopecia, pseudoanodontia (failure of tooth eruption), and progressive optic atrophy.
For patient information, click
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Muhammad Waleed, M.B.B.S. [1]
Synonyms and keywords:
Overview
GAPO syndrome is a rare, autosomal recessive disorder that causes severe growth retardation, and has been observed fewer than 30 times before 2011. GAPO is an acronym that encompasses the predominant traits of the disorder: growth retardation, alopecia, pseudoanodontia (teeth failing to emerge from the gums), and worsening optic atrophy in some subjects. Other common symptoms include premature aging, large, prominent foreheads, and delayed bone aging. GAPO syndrome typically results in premature death around age 30–40, due to interstitial fibrosis and atherosclerosis.
Historical Perspective
GAPO syndrome was first described in 1947. Since then, fewer than 60 cases have been reported in the medical literature up to the year 2021.
Classification
GAPO syndrome is caused by homozygous nonsense or splicing mutations in the ANTXR1 gene located on chromosome 2p13.3. This gene encodes anthrax toxin receptor 1, also known as tumor endothelial marker 8 (TEM8). The inheritance pattern is autosomal recessive, and genetic counseling is recommended for at-risk couples to inform them that each pregnancy carries a 25% risk of having an affected child
Pathophysiology
GAPO syndrome is a genetic disorder resulting from mutations in the ANTXR1 gene, leading to dysfunctional anthrax toxin receptor 1. Symptoms may begin to appear in infancy or early childhood.
Cause
GAPO syndrome is a genetic disease, which means that it is caused by one or more genes not working correctly.Disease-causing variants, or differences, in the following gene(s) are known to cause this disease: ANTXR1
Clinical features
- Growth Retardation: Individuals with GAPO syndrome exhibit slow skeletal formation, resulting in below-average height.
- Alopecia (Hair Loss): Hair is typically thinly dispersed and fragile, often leading to baldness later in life.
- Pseudoanodontia: Tooth growth is stunted, with teeth failing to emerge from the gums or develop normally.
- Progressive Optic Atrophy: Approximately one-third of individuals experience optic nerve atrophy, leading to peripheral vision impairment and difficulty distinguishing colors.
- Facial Features: While not defining, most individuals with GAPO syndrome have coarse facial features, including a large forehead, depressed nose bridges, protruding ears, and thick lips.
- Mental Function: There is no direct correlation between GAPO syndrome and mental retardation, although some cases of co-occurrence have been reported.
Epidemiology and Demographics
Approximately 60 patients with GAPO syndrome have been reported in literature since the first description in 1947.
Risk Factors
There are no specific risk factors associated with the development of GAPO syndrome.
Screening
There are no established screening programs for GAPO syndrome.
Natural History, Complications and Prognosis
GAPO syndrome has no curative treatment. Management primarily involves ophthalmologic surveillance and addressing symptomatic health problems. Individuals with GAPO syndrome generally have a reduced lifespan, typically living until the fourth to sixth decade of life.
Diagnosis
Diagnosis mostly relies on physical and ophtamologic examination. Additionally skin biopsy, cerebral angiography and magnetic resonance imaging contribute to more specific diagnosis.Prenatal diagnosis is not possible from fetal ultrasound (US). In utero growth retardation may be observed on US but is not specific.
Treatment
There is no curative treatment. Management mostly relies on ophthalmologic surveillance and symptomatic treatment of the multiple health problems.GAPO patients are reported to have a reduced lifespan (until the fourth to sixth decade of life